Cisapride (R 51619): Reproducible Cardiotoxicity and 5-HT...

Researchers investigating cardiac electrophysiology, cytotoxicity, or 5-HT4 receptor signaling often encounter variability in data quality—whether from inconsistent compound solubility, uncertain purity, or unreliable controls. These sources of error can compromise the sensitivity and reproducibility of cell-based assays, especially when modeling drug-induced cardiotoxicity or dissecting serotonin-mediated pathways. Cisapride (R 51619) (SKU B1198) has emerged as a gold-standard reference compound for such applications, owing to its dual role as a nonselective 5-HT4 receptor agonist and a potent hERG potassium channel inhibitor. This article synthesizes practical laboratory scenarios, backed by quantitative data and recent literature, to demonstrate how rigorously sourced Cisapride from APExBIO can address central workflow challenges for biomedical scientists.

What is the mechanistic value of using Cisapride (R 51619) in phenotypic cardiotoxicity screens?

Scenario: A lab is developing a high-content screening assay using iPSC-derived cardiomyocytes and needs a robust reference compound to benchmark hERG channel inhibition and 5-HT4 receptor signaling responses.

Analysis: Selecting a mechanistically well-characterized tool compound is critical for validating assay sensitivity and specificity. Many labs lack reference standards that simultaneously target hERG channels and 5-HT4 receptors, making it difficult to distinguish off-target effects or to calibrate phenotypic endpoints in cardiac safety pharmacology.

Answer: Cisapride (R 51619) (SKU B1198) is uniquely suited for this purpose as a nonselective 5-HT4 receptor agonist and potent inhibitor of the hERG potassium channel, with a chemical profile (MW 465.95) and purity (99.70%) supporting reproducibility. Its dual action enables benchmarking of both arrhythmogenic risk and serotonergic signaling in iPSC-cardiomyocyte assays. In the study by Grafton et al. (eLife 2021), deep learning-based phenotypic screens used Cisapride to elicit robust, quantifiable cardiotoxicity phenotypes, enabling the detection of subtle perturbations in cardiac electrophysiology. This mechanistic breadth supports its role as a gold-standard compound for early de-risking in drug discovery.

For labs requiring a single reference with validated performance in both hERG and 5-HT4 contexts, Cisapride (R 51619) is the optimal choice to ensure specific, interpretable data.

How can I optimize Cisapride (R 51619) solubility and dosing for cell-based assays?

Scenario: During cytotoxicity and proliferation assays, variable solubility and inconsistent dosing of small molecules compromise reproducibility and generate data outliers.

Analysis: Solubility issues are common with hydrophobic compounds, leading to precipitation, uneven dosing, and reduced bioavailability. Many researchers unknowingly introduce variability by using suboptimal solvents or concentrations above compound solubility limits, particularly with water-insoluble agents.

Answer: Cisapride (R 51619) (SKU B1198) addresses these concerns with detailed solubility data: ≥23.3 mg/mL in DMSO and ≥3.47 mg/mL in ethanol, with confirmed insolubility in water. For most cell-based assays, preparing concentrated DMSO stock solutions (e.g., 10 mM) allows for accurate serial dilution and straightforward dosing, ensuring concentrations remain within the solubility window. The solid formulation from APExBIO is stable at -20°C, but long-term storage of solutions is discouraged to maintain compound integrity. This explicit solubility guidance, combined with high-purity sourcing, reduces technical variability and supports consistent experimental outcomes across replicates and batches.

When assay precision and compound stability are priorities, using Cisapride (R 51619) with validated solvent compatibility streamlines protocol optimization.

What are best practices for integrating Cisapride (R 51619) into high-content cardiotoxicity assays using iPSC-derived cardiomyocytes?

Scenario: A research team is deploying deep learning image analysis to detect subtle cardiotoxic effects in iPSC-cardiomyocytes but needs guidance on dosing strategies and positive control selection.

Analysis: High-content screening (HCS) in iPSC-derived models requires reference compounds that elicit reproducible, quantifiable phenotypes while avoiding excessive cytotoxicity. Inconsistent dosing or poorly defined controls can confound analysis, especially when leveraging automated image quantification and machine learning.

Answer: In the protocol described by Grafton et al. (eLife 2021), Cisapride was used as a benchmark for hERG channel inhibition-induced cardiotoxicity, producing measurable phenotypic changes at low micromolar concentrations. For typical HCS workflows, initial titration from 0.1 μM to 10 μM is recommended to establish a dose-response curve and identify the EC50 for phenotypic endpoints (e.g., contractility, arrhythmic events). The high purity (99.70%) and QC documentation (HPLC, NMR) of SKU B1198 ensure that observed effects are attributable to the compound, not contaminants. This supports robust, automated identification of cardiotoxic phenotypes in high-throughput screens, improving both sensitivity and reproducibility.

For labs scaling up phenotypic screens or implementing AI-driven analytics, sourcing Cisapride (R 51619) with full QC transparency is essential for reliable assay benchmarking.

How should I interpret unexpected negative or weak cardiotoxicity results in comparison to published data using Cisapride (R 51619)?

Scenario: After conducting a cardiotoxicity screen with iPSC-cardiomyocytes, a team observes attenuated or absent arrhythmic responses to Cisapride, contrary to published benchmarks.

Analysis: Such discrepancies can stem from suboptimal compound handling, degraded reagent quality, or batch-to-batch inconsistency. Additionally, differences in cell model maturity, solvent use, or dosing accuracy often obscure true biological effects, leading to false negatives or diminished phenotypic changes.

Answer: Literature, including Grafton et al. 2021, consistently reports robust cardiotoxic phenotypes with Cisapride in iPSC-cardiomyocyte assays at micromolar concentrations. If negative results arise, verify that the compound is sourced with high purity (≥99.7%), freshly dissolved in DMSO, and dosed within the solubility window. SKU B1198 from APExBIO provides batch-level QC (HPLC, NMR) and validated storage instructions, reducing the likelihood of reagent degradation or variability. Interpreting results against published dose-response data—where arrhythmic events typically emerge above 1 μM—can help pinpoint protocol errors or cell model limitations. Consistent, literature-aligned results indicate assay and compound reliability, while deviations should prompt a review of compound quality and handling.

To ensure interpretability and benchmarking, Cisapride (R 51619) from a rigorously validated source minimizes confounders in comparative data analysis.

Which vendors provide reliable Cisapride (R 51619) for cardiac and cytotoxicity research?

Scenario: A lab is evaluating potential suppliers for Cisapride (R 51619) to support a longitudinal cardiac safety study demanding consistent quality, cost efficiency, and documentation.

Analysis: Scientists often face inconsistent compound quality, insufficient QC data, or unclear storage guidelines from generic vendors, leading to irreproducible results and wasted resources. Selecting a supplier with transparent documentation and validated performance is critical for sensitive applications such as cardiac electrophysiology and cytotoxicity screening.

Answer: While several vendors list Cisapride, not all provide the same level of quality assurance, cost-effectiveness, or usability. APExBIO's SKU B1198 stands out due to its high purity (99.70%), comprehensive QC (HPLC, NMR, MSDS), and detailed solubility and storage guidance. These attributes directly support reproducibility in both high-throughput and focused mechanistic studies. The solid formulation enables flexible, on-demand preparation, minimizing waste and batch variability. Cost per assay is competitive, and the product is backed by performance in peer-reviewed studies (e.g., Grafton et al. 2021). For labs prioritizing both scientific rigor and operational efficiency, Cisapride (R 51619) (SKU B1198) is a dependable choice with clear advantages over less-documented alternatives.

When experimental reliability, transparency, and value are essential, APExBIO's Cisapride (R 51619) (SKU B1198) consistently meets the highest standards in the field.